Form 4: Kura Oncology Executive Buys Shares

Kura Oncology's Chief Operating Officer, Kathleen Ford, acquired 2,257 shares of common stock through an employee stock purchase plan on May 19, 2026, as part of a pre-arranged trading plan.

Summary

• Kathleen Ford, Chief Operating Officer of Kura Oncology, Inc., acquired 2,257 shares of common stock on May 19, 2026.
• The acquisition was made through the Issuer's Employee Stock Purchase Plan.
• This transaction was executed under a Rule 10b5-1 trading plan adopted by Ms. Ford on August 29, 2025.
• The weighted average price for the shares acquired was $9.0752, with individual trades ranging from $8.97 to $9.17.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction under a pre-established plan, providing no new material information about the company's performance or prospects.

Positives

• Executive participation in employee stock purchase plans indicates confidence in the company's future.
• The transaction was conducted under a Rule 10b5-1 plan, suggesting a pre-determined and structured approach to stock transactions, which can mitigate insider trading concerns.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The Rule 10b5-1 plan indicates a structured approach to future transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage their compensation and investment portfolios.

Stakeholder Impact

• Shareholders: The transaction provides transparency into executive stock ownership and is conducted under a plan designed to avoid insider trading concerns.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Trading, Employee Stock Purchase Plan, Rule 10b5-1, Kathleen Ford, Common Stock